GTx, Inc (NASDAQ:GTXI) Stock Decline


Dallas, Texas 03/26/2014 (FINANCIALSTRENDS) – GTx, Inc (NASDAQ:GTXI)’s major shareholder named Jack W. Schuler offloaded 1,192,251 GTx, Inc (NASDAQ:GTXI) shares in the open market in the transaction that was dated 21 March. These shares were sold-off at an average-price of $1.84, for a total-transaction of $2,193,741.84. Post this transaction, Schuler now directly-owns 6,165,261 GTx, Inc (NASDAQ:GTXI) shares, valued at around $11,344,080. This transaction was disclosed in the legal-filing with Securities & Exchange Commission,  GTx, Inc (NASDAQ:GTXI) last issued the company’s quarterly-earnings data on 4 March . It reported earnings per share of $0.12 for the quarter, which topped the average projection of $0.13 by $0.01. In the same quarter in the previous year, GTx, Inc (NASDAQ:GTXI) posted earnings per share of $0.17. On an average, analysts project that GTx, Inc (NASDAQ:GTXI) will post earnings per share of $-0.43 for the current financial year.

GTx, Inc (NASDAQ:GTXI) also recently announced that it had closed its previously-announced private-placement of common stock & warrants to buy its common stock. In this private placement, GTx, Inc (NASDAQ:GTXI) issued 11,976,048 immediately-separable units, that comprised of the aggregate of 11,976,048 newly-issued-shares of its common stock and the warrants to purchase upto 10,179,642 added shares of its common stock. The purchasers were J.R. Hyde, III, who is the chairman of GTx, Inc (NASDAQ:GTXI)’s Board of Directors & The Pyramid Peak Foundation. The gross proceeds from this offering were around $21.3M.

In connection with this private placement, GTx, Inc (NASDAQ:GTXI) has agreed, subject to the certain terms & conditions, to file the registration-statement under its Securities Act that covers the resale of its shares of common-stock that have been sold in this private placement, including shares of its common stock that underlie the warrants, within 180-days after closing. GTx, Inc (NASDAQ:GTXI) is a bio pharma company that is developing selective androgen- receptor modulators. These are drugs that have the potential to prevent & treat muscle- wasting in patients.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.